Immuron seeking FDA approval for travelers’ diarrhea drug candidate
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Australian biopharmaceutical company, Immuron Limited (ASX:IMC |NASDAQ:IMRN), plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.
IMC is focused on developing and commercialising oral immunoglobulin therapeutics for the treatment of gut mediated diseases and is pursuing a rapid path for clinical development of IMM-124E.
The company currently markets and sells Travelan® as a Therapeutic Goods Administration (TGA) listed medicine for prevention of travelers’ diarrhea in Australia, and also markets Travelan® in the US and Canada as a dietary supplement, and natural health product, respectively, for digestive tract protection.
Dr Gary S. Jacob, CEO of IMC highlighted that Travelan® and IMM-124E are one and the same. IMC is seeking FDA registration for IMM-124E as a drug to prevent travelers’ diarrhea, offering the potential for substantial sales benefits to Immuron.
Immuron forecasts IMM-124E’s potential peak annual sales at over US$100 million annually as an FDA approved drug to prevent TD.
Dr Jacob said, “This is an important strategic initiative towards enhancing commercialisation of the Travelan®/IMM-124E franchise”.
“We are moving aggressively forward to develop IMM-124E through the FDA by planning to file an Investigational New Drug (IND) application for prevention of travelers’ diarrhea, and pursuing with FDA a rapid path for its clinical development.”
IMM-124E recently completed a non-alcoholic steatohepatitis (NASH) trial and is currently being evaluated in ongoing clinical trials in alcoholic steatohepatitis (ASH) and pediatric non-alcoholic fatty liver disease (NAFLD).
IMC expect top-line data from the clinical trial of IMM-124E in ASH patients to be released by late Q2 2019.
Immuron is focused on establishing whether statistically-significant reductions in systemic lipopolysaccharide (LPS) endotoxin, observed in the completed Phase 2 trial in NASH patients, are observed in the ASH trial where lowering systemic LPS is the primary endpoint for the trial. Together with the completed trial in NASH patients, the company will be looking to determine IMM-124E’s potential in treating conditions where systemic LPS is believed to play a critical role.
Travelers diarrhea affects between 30% and 60% of over one billion international travellers every year and symptoms of nausea, vomiting, fever, stomach cramps and diarrhea, can last up to seven days. Travelan® has been shown in clinical studies to be an effective preventative against TD when taken as instructed.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.